Hot Investor Mandate 4: Hematology Enterprise Invests in Medical Technology for Blood and Liver Diseases

4 May

A China-based enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technology and mutual cooperation on China-USA market that are a strategic fit for its pipeline and marketing resources. Equity investment size can be flexible which is mostly regarding strategic collaboration but typically ranges from US$1-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.

The firm is interested in consumables and medical devices in the hematology, renal diseases and liver diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline.

The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: